These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 6193072)
1. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies. Charpin C; Bhan AK; Zurawski VR; Scully RE Int J Gynecol Pathol; 1982; 1(3):231-45. PubMed ID: 6193072 [TBL] [Abstract][Full Text] [Related]
2. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas. Fowler LJ; Maygarden SJ; Novotny DB Hum Pathol; 1994 Jul; 25(7):666-70. PubMed ID: 8026826 [TBL] [Abstract][Full Text] [Related]
3. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Neunteufel W; Breitenecker G Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183 [TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen in primary and metastatic ovarian tumors. Fleuren GJ; Nap M Gynecol Oncol; 1988 Jul; 30(3):407-15. PubMed ID: 2839395 [TBL] [Abstract][Full Text] [Related]
5. The expression of CEA, CA 19-9 and HMFG antigens in ovarian clear-cell and endometrioid carcinomas. Helle M; Helin H; Ashorn P; Putkinen EL; Krohn K; Wahlström T Pathol Res Pract; 1992 Feb; 188(1-2):74-7. PubMed ID: 1594502 [TBL] [Abstract][Full Text] [Related]
6. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen. Wu JT; Miya T; Knight JA; Knight DP Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203 [TBL] [Abstract][Full Text] [Related]
7. [An immunohistochemical study of intestinal mucinous antigens and CEA in ovarian epithelial tumors]. Liu A; Wang M; Li H Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):366-8. PubMed ID: 8732094 [TBL] [Abstract][Full Text] [Related]
8. Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors. Sakakibara K; Ueda R; Ohta M; Nakashima N; Tomoda Y; Takahashi T Cancer Res; 1988 Aug; 48(16):4639-45. PubMed ID: 2456145 [TBL] [Abstract][Full Text] [Related]
9. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. Thor A; Gorstein F; Ohuchi N; Szpak CA; Johnston WW; Schlom J J Natl Cancer Inst; 1986 Jun; 76(6):995-1006. PubMed ID: 3520078 [TBL] [Abstract][Full Text] [Related]
10. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Kabawat SE; Bast RC; Welch WR; Knapp RC; Colvin RB Am J Clin Pathol; 1983 Jan; 79(1):98-104. PubMed ID: 6336888 [TBL] [Abstract][Full Text] [Related]
11. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Sheahan K; O'Brien MJ; Burke B; Dervan PA; O'Keane JC; Gottlieb LS; Zamcheck N Am J Clin Pathol; 1990 Aug; 94(2):157-64. PubMed ID: 1695478 [TBL] [Abstract][Full Text] [Related]
12. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases. Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948 [TBL] [Abstract][Full Text] [Related]
13. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Berezowski K; Stastny JF; Kornstein MJ Mod Pathol; 1996 Apr; 9(4):426-9. PubMed ID: 8729984 [TBL] [Abstract][Full Text] [Related]
14. Identification of two different surface epitopes of human ovarian epithelial carcinomas by monoclonal antibodies. Tsuji Y; Suzuki T; Nishiura H; Takemura T; Isojima S Cancer Res; 1985 May; 45(5):2358-62. PubMed ID: 2580620 [TBL] [Abstract][Full Text] [Related]
15. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status. Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001 [TBL] [Abstract][Full Text] [Related]
16. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196 [TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors]. Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374 [TBL] [Abstract][Full Text] [Related]
18. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA. Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase. Shishi J; Ghazizadeh M; Oguro T; Aihara K; Araki T Am J Clin Pathol; 1986 May; 85(5):595-8. PubMed ID: 3518399 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and ultrastructural localization of T antigen in ovarian tumors. Ghazizadeh M; Oguro T; Sasaki Y; Aihara K; Araki T; Springer GF Am J Clin Pathol; 1990 Mar; 93(3):315-21. PubMed ID: 1689937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]